Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR12696782

—

b23e4dfd-8873-53ea-9988-4c2dc96fe463

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
  • HYPOXIA+0.500
  • ANGIOGENESIS+0.400
  • GLYCOLYSIS+0.400
  • TGF_BETA_SIGNALING+0.400
  • TNFA_SIGNALING_VIA_NFKB+0.400
  • UNFOLDED_PROTEIN_RESPONSE+0.400
  • CHOLESTEROL_HOMEOSTASIS+0.300
  • DNA_REPAIR+0.300
  • HEDGEHOG_SIGNALING+0.300

Top 10 suppressed

  • KRAS_SIGNALING_DN-0.300
  • ALLOGRAFT_REJECTION-0.200
  • BILE_ACID_METABOLISM-0.200
  • INTERFERON_GAMMA_RESPONSE-0.200
  • SPERMATOGENESIS-0.200
  • APICAL_SURFACE-0.100
  • INTERFERON_ALPHA_RESPONSE-0.100
  • ESTROGEN_RESPONSE_EARLY+0.000
  • ESTROGEN_RESPONSE_LATE+0.000
  • IL6_JAK_STAT3_SIGNALING+0.000

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-68-7756-01A-11R-2125-07
lung-landscapes@6
—cohortSQ10.861
2TCGA-78-7145-01A-11R-2039-07
lung-landscapes@6
—cohortA10.820
3TCGA-66-2734-01A-01R-0980-07
lung-landscapes@6
—cohortSQ10.816
4BS_23M72ABG
brain-umap@2
Meningioma—0.814
5BS_30VC3R2Q
brain-umap@2
Diffuse intrinsic pontine glioma—0.802
6SRR12696796
melanoma-umap@29
——0.794
7MNG252
mng-umap@100
——0.793
8BS_KP735TJ6
brain-umap@2
high-grade glioma—0.792
9TCGA-UY-A8OC-01A-11R-A36F-07
bladder-landscape@3
——0.790
10SRR934963
brain-umap@2
——0.783

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 37 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.500Inavolisib— uncovered
HYPOXIA0.500Idelalisib— uncovered
ANGIOGENESIS0.400Remibrutinib— uncovered
GLYCOLYSIS0.400Inavolisib— uncovered
TGF_BETA_SIGNALING0.400Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.400Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.400Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.300Remibrutinib— uncovered
DNA_REPAIR0.300Idelalisib— uncovered
HEDGEHOG_SIGNALING0.300Inavolisib— uncovered
MITOTIC_SPINDLE0.300Inavolisib— uncovered
MTORC1_SIGNALING0.300Inavolisib— uncovered
P53_PATHWAY0.300Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.300Inavolisib— uncovered
ADIPOGENESIS0.200Inavolisib— uncovered
APICAL_JUNCTION0.200Inavolisib— uncovered
APOPTOSIS0.200Idelalisib— uncovered
G2M_CHECKPOINT0.200Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.200Idelalisib— uncovered
MYC_TARGETS_V10.200Inavolisib— uncovered